Position in SYRE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$95,865,356
+$33,602,290 QoQ
Shares Held
1,900,582
0.0% QoQ
Ownership
2.19%
of shares outstanding
% of Portfolio
2.74%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026TCG Crossover Management, LLC holds $3,218,747,876 across 44 Biotechnology names. SYRE ranks #11 (3.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
6,481,085 | $721,668,814 | |
| 2 | CGON |
CG Oncology, Inc.
|
3,670,206 | $248,399,542 | |
| 3 | TNGX |
Tango Therapeutics, Inc.
|
10,531,071 | $220,310,005 | |
| 4 | COGT |
Cogent Biosciences, Inc.
|
4,946,894 | $190,405,950 | |
| 5 | CNTA |
Centessa Pharmaceuticals plc
|
4,286,480 | $170,258,985 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
1,676,624 | $140,702,286 | |
| 7 | TYRA |
Tyra Biosciences, Inc.
|
3,248,980 | $124,435,934 | |
| 8 | IMVT |
Immunovant, Inc.
|
4,457,988 | $110,736,421 |
All Filings in SYRE
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $95,865,356 | 1,900,582 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $62,263,066 | 1,900,582 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $18,445,754 | 1,100,582 | Shares | Sole | 2025-11-17 | |
| No filing history on record for this holder in this stock. | ||||||